Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- James A. Helliwell
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 49
- Beta
- 1.50
- Country
- CA
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 18.27
Financials
Net Income
$-14.49MEBITDA
$-14.33MFree Cash Flow
$-12.92MEPS (diluted)
$-0.23Shares Outstanding (diluted)
66.22M+414.7%Operating Expenses
$18.10MCash & Debt
$133.40MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-38.58M | $-1.03 |
| 2024 | $0.00 | $-25.50M | $-0.76 |
| 2023 | $0.00 | $-21.25M | $-0.88 |
| 2022 | $0.00 | $-18.49M | $-0.96 |
| 2021 | $0.00 | $-23.96M | $-1.93 |
| 2020 | $0.00 | $-4.01M | $-0.31 |
| 2019 | $0.00 | $-7.37M | $-0.56 |
| 2018 | $0.00 | $-13.19M | $-1.03 |
| 2017 | $0.00 | $-4.38M | $-0.34 |
Valuation
EPRXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
83-16.67%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·6d ago·Negative
…tment of Eosinophilic Esophagitis VANCOUVER, British Columbia, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced updated clinical data from the Phase 1b/2a RESOLVE study highlighting the long duration of response, high remis…
View source ↗ - Newsglobenewswire.com·54d ago·Negative
…ed Serious Adverse Events (“SAEs”) VANCOUVER, British Columbia, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced positive results from a new analysis of the RESOLVE study examining the effect of EP-104GI on symptom severity,…
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results New data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI
View source ↗ - Newszacks.com·56d ago·Neutral
Wall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Really Move This High? The consensus price target hints at a 145.4% upside potential for Eupraxia Pharmaceuticals Inc. (EPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $-0.26 per share
Typical surprise -10.5% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.16 vs $-0.23beat
- Tue, May 12$-0.23 vs $-0.22miss
- Thu, Mar 12$-0.37 vs $-0.16miss
- Tue, Nov 4$-0.19 vs $-0.23beat
- Tue, Aug 12$-0.26 vs $-0.21miss
- Tue, May 6$-0.21 vs $-0.19miss
Estimates and results for EPRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in EPRX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.